- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Sanofi Announces New Global Business Unit Structure
July 15, 2015.
Sanofi has announced plans to evolve its business with the creation of five global business units: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur, and Merial. The new structure will be implemented beginning in January 2016, the company states.
According to its press statement, Sanofi is now poised "to achieve significant growth with the potential of launching up to six new medicines in 2015 and approximately one new medicine every six months between 2016 and 2018".
The General Medicines & Emerging Markets unit will be led by Peter Guenter and will consist of Sanofi's Established Products, Generics, Consumer Healthcare, and all pharmaceutical businesses in emerging markets.
The Specialty Care global business unit, to be called Sanofi Genzyme, will be led by David Meeker and will consist of medicines in rare diseases, multiple sclerosis, oncology and immunology, including the two, investigational biologics, sarilumab and dupilumab.
The Diabetes & Cardiovascular unit will be led by Pascale Witz and will consist of Sanofi's Diabetes Care medicines as well as Cardiovascular.
Olivier Charmeil will continue to lead Sanofi Pasteur and Carsten Hellmann will continue to lead Merial, and these units will continue with their current portfolios of vaccines and animal health products.
Sanofi states that the composition of the Executive Committee remains unchanged. The new leadership roles are effective from January 1st, 2016.
